Pliant Therapeutics (PLRX) Change in Account Payables (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Change in Account Payables of -$118000.0 for Q1 2026, up 65.09% year-over-year from -$71476.7 in Q1 2025, and down 3833.33% quarter-over-quarter from -$3000.0 in Q4 2025.
Pliant Therapeutics (PLRX) Change in Account Payables (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Change in Account Payables for 8 consecutive years, with -$118000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 65.09% year-over-year to -$118000.0; the TTM figure through Mar 2026 stood at -$5.3 million (down 350.73% YoY), while the FY2025 annual figure was -$5.5 million, down 483.75% from the prior year.
- Change in Account Payables eased to -$118000.0 in Q1 2026 per PLRX's latest filing, from -$3000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.7 million in Q3 2024 and bottomed at -$4.2 million in Q2 2025.
- Historically, Change in Account Payables has averaged -$150117.6 across 5 years, with a median of -$118000.0 in 2026.
- Annual changes were most pronounced in 2022 — Change in Account Payables plunged 2163.16% — and 2023, when it jumped 1936.54%.
- Pliant Therapeutics' Change in Account Payables stood at -$1.6 million in 2022, then jumped by 173.02% to $1.2 million in 2023, then tumbled by 179.35% to -$930000.0 in 2024, then soared by 99.68% to -$3000.0 in 2025, then slumped by 3833.33% to -$118000.0 in 2026.
- Business Quant data shows PLRX's Change in Account Payables at -$118000.0 in Q1 2026, -$3000.0 in Q4 2025, and -$897000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | 1.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Mn |
| Jun 30, 2026 | 1.17 Mn |
| Mar 31, 2026 | -118,000.00 |
| Mar 31, 2026 | -118,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | -897,000.00 |
| Sep 30, 2025 | -897,000.00 |
| Jun 30, 2025 | -4.24 Mn |
| Jun 30, 2025 | -4.24 Mn |
| Mar 31, 2025 | -338,000.00 |
| Mar 31, 2025 | -338,000.00 |
| Dec 31, 2024 | -930,000.00 |
| Dec 31, 2024 | -930,000.00 |
| Sep 30, 2024 | 3.73 Mn |
| Sep 30, 2024 | 3.73 Mn |
| Jun 30, 2024 | -3.63 Mn |
| Jun 30, 2024 | -3.63 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |